Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-168525
Filing Date
2026-04-22
Accepted
2026-04-22 08:01:44
Documents
17
Period of Report
2026-06-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A d94391ddef14a.htm   iXBRL DEF 14A 557338
3 GRAPHIC g94391g00k07.jpg GRAPHIC 175357
4 GRAPHIC g94391g00k08.jpg GRAPHIC 179444
5 GRAPHIC g94391g16g16.jpg GRAPHIC 32780
6 GRAPHIC g94391g93e01.jpg GRAPHIC 149838
7 GRAPHIC g94391g94e01.jpg GRAPHIC 161138
  Complete submission text file 0001193125-26-168525.txt   2834696

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tsha-20251231.xsd EX-101.SCH 3159
20 EXTRACTED XBRL INSTANCE DOCUMENT d94391ddef14a_htm.xml XML 108623
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39536 | Film No.: 26881323
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)